Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Nucana ( (NCNA) ) just unveiled an announcement.
On July 11, 2025, NuCana plc announced a change in the ratio of its American Depositary Shares (ADSs) to ordinary shares, shifting from one ADS representing twenty-five ordinary shares to one ADS representing five thousand ordinary shares. This adjustment, effective August 8, 2025, is equivalent to a one-for-two hundred reverse ADS split and aims to enhance liquidity and help the company comply with Nasdaq’s minimum bid price requirement. The change is expected to proportionally increase the ADS trading price, although there is no assurance of its impact on liquidity.
The most recent analyst rating on (NCNA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Nucana stock, see the NCNA Stock Forecast page.
Spark’s Take on NCNA Stock
According to Spark, TipRanks’ AI Analyst, NCNA is a Underperform.
Nucana’s overall score is primarily impacted by its financial instability and negative valuation metrics. The significant lack of revenue generation and operational losses are major concerns. Despite showing strong cash management and low leverage, the company’s technical indicators suggest a bearish trend, further weighing down the score. The poor valuation metrics, such as a negative P/E ratio, are offset by potential speculative interest due to the low stock price. The absence of notable earnings call insights or corporate events means these factors did not influence the score.
To see Spark’s full report on NCNA stock, click here.
More about Nucana
NuCana is a clinical-stage biopharmaceutical company focused on improving cancer treatment outcomes by utilizing its ProTide technology to enhance the efficacy and safety of chemotherapy agents. The company is developing new medicines, such as NUC-7738 and NUC-3373, aimed at overcoming the limitations of conventional nucleoside analogs, which are commonly used in treating solid and hematological tumors.
Average Trading Volume: 197,276,833
Technical Sentiment Signal: Sell
Current Market Cap: $23.01M
For an in-depth examination of NCNA stock, go to TipRanks’ Overview page.